Patents Examined by Sarae L Bausch
  • Patent number: 11965216
    Abstract: Provided herein are media, methods, kits, primers and oligonucleotide probes for use in the molecular detection of pathogens. These may be used in combination for the rapid, high-throughput screening PCR-based techniques to simultaneously detect multiple pathogens. The multiplex-detection methods have improved sensitivity and specificity for the detection of multiple pathogens simultaneously. Real-time PCR assaying techniques using such primers include microarrays and multiplex arrays, the latter optionally simultaneously with oligonucleotide TaqMan probes.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: April 23, 2024
    Assignee: POLYSKOPE LABS
    Inventors: Cyrus Cody Zegrati, Michael Benjamin Centola, Bobby Alfonso Gramling, Jr., Paul Simon Smith
  • Patent number: 11946107
    Abstract: Provided herein are methods and compositions for detecting Salmonella typhimurium in a sample.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: April 2, 2024
    Assignee: Bio-Rad Europe GmbH
    Inventors: Jean-Francois Mouscadet, Sophie Pierre
  • Patent number: 11913066
    Abstract: Disclosed are primer set compositions, methods and kits for human identification using the highly complex sequence locus, SE33 (ACTBP2) in single and multiplex PCR reactions. Additionally, disclosed are three newly discovered single nucleotide polymorphisms (SNPs) within the SE33 locus that can cause discordance seen as mobility shift or allelic dropout. Also disclosed are kits useful in human identification.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: February 27, 2024
    Assignee: Life Technologies Corporation
    Inventors: Robert Green, Dennis Wang, Julio Mulero, Robert Lagace
  • Patent number: 11898195
    Abstract: Described herein are nucleic acid molecules and complexes useful as i-switch pH reporters that have increased sensitivities as a pH reporter and have alternate pH reporting capacity ranges. Aspects of the disclosure relate to a method for determining pH comprising providing a nucleic acid complex comprising: a first single-stranded nucleic acid molecule comprising the sequence CnXCnYCnZCn (SEQ ID NO.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: February 13, 2024
    Assignees: The University of Chicago, The National Centre for Biological Sciences
    Inventors: Yamuna Krishnan, Saheli Halder
  • Patent number: 11879160
    Abstract: The present disclosure provides a molecular marker for identifying traits of efficiency of duck feed utilization based on a neuropeptide gene NPY, a method and use thereof. The NPY gene has a nucleotide sequence shown in SEQ ID NO: 1, the molecular marker is T or C, and the molecular marker is located at position 577 of the nucleotide sequence. In the present disclosure, mutation of the NPY gene is detected using a polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) method, the traits of efficiency of duck feed utilization are selected based on genotypes, and a breeding method for early selection of efficiency of poultry feed utilization is established. The method is simple, rapid, and low-cost, does not need special instrument, and satisfies experimental needs.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: January 23, 2024
    Assignee: Anhui Agricultural University
    Inventors: Sihua Jin, Zhaoyu Geng, Hongfeng Jiang, Fei Shui, Jingjing Xia, Yuqing Jia, Chengcheng Cao, Yuanfei Ding, Taikang Zhang, Fumin Jia
  • Patent number: 11873525
    Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.
    Type: Grant
    Filed: May 23, 2023
    Date of Patent: January 16, 2024
    Assignee: SERB SA
    Inventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
  • Patent number: 11851715
    Abstract: Methods and compositions are provided for determining a pan-cancer clustering of cluster assignment (COCA) subtype of a cancer in an individual by detecting the expression level of at least one classifier biomarker selected from a group of classifier biomarkers for COCA subtypes. Also provided herein are methods and compositions for determining the response of an individual with a COCA subtype to a therapy such as immunotherapy.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 26, 2023
    Assignees: GeneCentric Therapeutics, Inc., The University of North Carolina at Chapel Hill
    Inventors: Greg Mayhew, Hawazin Faruki, Myla Lai-Goldman, Charles M. Perou, Joel S. Parker
  • Patent number: 11845977
    Abstract: Provided herein are methods of determining NAT acetylation status of a subject with a 3,4-DAP-sensitive disease, methods of selecting a dose of 3,4-DAP or a pharmaceutically acceptable salt thereof adjusted to a subject's acetylation status, methods of administering 3,4-diaminopyridine or a pharmaceutically acceptable salt thereof to a patient in need thereof, and methods of treating 3,4-DAP sensitive diseases.
    Type: Grant
    Filed: May 23, 2023
    Date of Patent: December 19, 2023
    Assignee: SERB SA
    Inventors: Marvin R. Garovoy, Peter E. Haroldsen, Donald G. Musson
  • Patent number: 11840738
    Abstract: A method for determining a risk of urothelial carcinoma may be based on the methylation level of DNA. A method for determining a risk of canceration of a urothelial tissue may involve detecting the DNA methylation level of a CpG site of at least one gene selected from TENM3, HOXC4, TLR1, CPVL and PRDM16 in genomic DNA preferably derived from a urothelial cell or a tissue containing the urothelial cell; and determining a risk of canceration of the urothelial tissue from the detected DNA methylation level.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: December 12, 2023
    Assignee: KEIO UNIVERSITY
    Inventors: Yae Kanai, Eri Arai
  • Patent number: 11840739
    Abstract: The present invention provides a composition, a kit and the use thereof, as well as the method for detecting the cell proliferative abnormality in individuals or grading the disease degree in the individuals. The composition comprises nucleic acids for detecting the methylation level within at least one target region of a gene and the fragment thereof.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: December 12, 2023
    Assignee: Biochain(Beijing) Science & Technology, Inc.
    Inventors: Xiaoliang Han, Tong Lu, Kaichun Wu, Yongzhan Nie, Daiming Fan, James Jianming Wang
  • Patent number: 11834719
    Abstract: Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: December 5, 2023
    Assignee: MYRIAD MYPATH, LLC
    Inventors: Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
  • Patent number: 11821045
    Abstract: Provided is a colorectal cancer-specific methylation biomarker for diagnosing colorectal cancer. Since a gene marker according to an embodiment exhibits a specific methylation pattern in colorectal cancer tissue, it can be usefully used as a methylation marker for diagnosing colorectal cancer, thereby increasing the cure rate of colorectal cancer by early diagnosis and treatment of colorectal cancer.
    Type: Grant
    Filed: April 13, 2021
    Date of Patent: November 21, 2023
    Assignees: GENINUS INC., SAMSUNG LIFE PUBLIC WELFARE FOUNDATION
    Inventors: Jinho Kim, Woong Yang Park, Yong Beom Cho, Ga Hyun Kim, Jun Gi Jeong, Dong Hyun Park
  • Patent number: 11788154
    Abstract: Provided is a method for identifying a racehorse including amplifying a target gene by a multiplex PCR using a microsatellite marker obtained by combining one or more sets selected from a first set consisting of AHT4, AHT5, ASB2, HMS3, HMS6, HMS7, HTG4, HTG10, VHL20, ASB17, ASB23, HMS1, LEX3, CA425, HMS2, HTG6, HTG7, LEX033, AMEL, HMS18, LEX27, SRY, and LEX020 and a second set consisting of HTG21, COR089, TKY279, TKY287, TKY294, TKY297, TKY301, TKY312, TKY321, TKY325, TKY333, TKY337, TKY341, TKY343, TKY344, TKY374, and TKY394; detecting alleles in the product amplified in the multiplex PCR amplification step and analyzing the sizes of the alleles using an electrophoresis apparatus to determine a genotype of the racehorse; and summarizing the sizes of the alleles analyzed using the electrophoresis apparatus according to the population and breed of racehorses to plot the number and a frequency distribution of the alleles based on the summarized results.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: October 17, 2023
    Assignee: Korea Racing Authority
    Inventors: Daeha Choi, Sunyoung Lee, Shinwook Kang, Manbea Hu, Jundong Yu, Hyuncheol Lee
  • Patent number: 11773454
    Abstract: Provided is a multiplex PCR amplification method for identifying an unknown biological sample suspected to be from a human. The method comprises the following steps: 1) acquiring an unknown biological sample suspected to be from a human and which is to be detected; 2) directly adding said unknown sample or nucleic acid extracted from said unknown sample to a premixed PCR reagent; 3) running a PCR amplification program to conduct a multiplex PCR amplification reaction; and 4) detecting and analyzing PCR amplification products, wherein the premixed PCR reagent contains primers specific to human genetic markers and primers specific to nuclear chromosomal genes of non-human species. Also provided is a multiplex PCR amplification kit for species and human individual recognition and identification of an unknown biological sample.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: October 3, 2023
    Assignee: NINGBO HEALTH GENE TECHNOLOGIES CO., LTD.
    Inventors: Ding Yu, Yong Wu, Haiying Jin, Kang Wang
  • Patent number: 11725232
    Abstract: Provided herein are methods, kits, and devices related to genetic variations of neurological disorders. For example, methods, kits, and devices for using such genetic variations to assess susceptibility of developing Alzheimer's disease.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: August 15, 2023
    Assignee: The Hong Kong University of Science and Technology
    Inventors: Nancy Yuk-Yu Chu Ip, Kit Yu Fu, Yu Chen, Xiaopu Zhou
  • Patent number: 11713486
    Abstract: The present invention provides combinations of biomarkers that can be used in the diagnosis and differentiation of bipolar disorder and schizophrenia. The present invention therefore provides methods of differentiating, diagnosing and treating bipolar disorder and schizophrenia, by examining relevant proteins and RNA in a patient sample.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 1, 2023
    Assignees: The Regents of the University of California, Laguna Diagnostics, LLC
    Inventors: Terry W. Osborn, Marquis Vawter
  • Patent number: 11667976
    Abstract: TERT promoter mutations occur in both papillary and flat lesion bladder cancers, are the most frequent genetic alterations identified to date in noninvasive precursor lesions of the bladder, are detectable in urine, and appear to be strongly associated with bladder cancer recurrence. The TERT promoter mutations are useful urinary biomarker for both the early detection and monitoring of bladder neoplasia.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: June 6, 2023
    Assignee: The Johns Hopkins University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Luis Diaz, Nickolas Papadopoulos, George J. Netto, Ralph Hruban, Isaac A. Kinde
  • Patent number: 11649504
    Abstract: The present invention relates to a set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival or of predicting the likelihood of a recurrence and/or aggressiveness of a breast cancer in a breast cancer patient. The present invention also relates to a method for predicting the likelihood of a breast cancer patient's survival or the likelihood of the recurrence or aggressiveness of a breast cancer in a breast cancer patient, as well as to a kit for use in such method.
    Type: Grant
    Filed: February 4, 2017
    Date of Patent: May 16, 2023
    Assignee: KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE
    Inventors: Khalid S. Abu Khabar, Tala Bakheet, Edward Hitti, Nora Al-Souhibani, Adher Alsayed, Taher Twegieri, Asma Tulbah
  • Patent number: 11634748
    Abstract: Methods are provided for the epigenetic analysis of cell-free DNA using organic boranes to convert oxidized 5-methylcytosine residues in the cell-free DNA to dihydrouracil (DHU) residues. Cell-free DNA is contacted with an organic borane selected to successively bring about reduction, deamination, and decarboxylation of oxidized 5-methylcytosine residues such as 5-carboxymethylcytosine and 5-formylcytosine, resulting in DHU residues in place thereof. Following amplification, the treated cell-free DNA is sequenced, with the DHU residues read as thymine residues. Reaction mixtures, kits and additional methods are also provided, as are related methods for the epigenetic analysis of DNA, including cell-free DNA.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: April 25, 2023
    Assignee: CLEARNOTE HEALTH, INC.
    Inventors: Patrick A. Arensdorf, Damek Spacek
  • Patent number: 11584967
    Abstract: Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
    Type: Grant
    Filed: February 10, 2020
    Date of Patent: February 21, 2023
    Assignee: MYRIAD MYPATH, LLC
    Inventors: Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake